Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SOLAI Limited (SLAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SOLAI Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while SOLAI Limited trades at $3.17 (market cap $14.40M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 311.8× SOLAI Limited's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| ACAD | SLAI | |
|---|---|---|
Market Cap | $4.49B | $14.40M |
Sector | Health | Technology |
52-Week High | $28.06 | $43.75 |
52-Week Low | $20.06 | $2.74 |
Enterprise Value | $3.69B | $14.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SLAI trades at $3.27, up 5.48% today, but faces significant financial challenges with negative profitability metrics including a -134.63% net income margin and -$33.88M net loss for 2025. The company recently completed a 7:1 reverse stock split and acquired a 51% stake in NEURALAND while receiving NYSE listing standard notices. Technical indicators show a bearish trend with support at $3 and resistance at $4.
Despite recent acquisitions and product launches, SLAI's persistent losses and negative cash flow present substantial investment risks. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment amid ongoing financial restructuring and competitive pressures in the AI infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
